Company profile: Diatech Pharmacogenetics
1.1 - Company Overview
Company description
- Provider of pharmacogenetics tests and precision medicine diagnostic solutions: Real Time PCR for variants of clinical interest in solid tumors and infectious diseases; Next Generation Sequencing equipment, libraries, and bioinformatics for SNPs, In/Del, CNV, and gene fusions in solid tumors; Pyrosequencing and fragment analysis for somatic or germline variants; and oncology equipment, kits, and software for analysis using MassArray technology.
Products and services
- Next Generation Sequencing: Delivers equipment, libraries, and bioinformatics components for analyzing SNPs, In/Del, CNV, and gene fusions in solid tumors, NGS-based
- Real Time PCR: Supplies complete systems for analyzing clinical interest variants in solid tumors and infectious diseases using Real Time PCR technology, PCR-based
- Pyrosequencing & Fragment Analysis: Produces complete diagnostic assemblies to analyze somatic or germline genetic variants through Pyrosequencing and fragment analysis, pyrosequencing-based
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Diatech Pharmacogenetics
Exousia Pro
HQ: United States
Website
- Description: Provider of exosome-based therapeutics for cancer and other diseases, with research in plant-derived exosomes and integration of AI to support development.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Exousia Pro company profile →
Kura Oncology
HQ: United States
Website
- Description: Provider of precision medicines for solid tumors and blood cancers, advancing investigational therapies including ziftomenib for AML with specific mutations, tipifarnib for HRAS-mutant head and neck squamous cell carcinoma and other cancers, and KO-2806, a next-generation FTI for advanced solid tumors; also conducts clinical trials and offers expanded access programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kura Oncology company profile →
Oxford BioTherapeutics
HQ: United Kingdom
Website
- Description: Provider of targeted cancer medicines and companion diagnostics for selected antibody programs, developing a broad pipeline of novel antibody therapeutics using its OGAP (Oxford Genome Anatomy Project) platform, supported by strategic partnerships with leading antibody companies including Medarex, Biosite and Amgen.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Oxford BioTherapeutics company profile →
Sareum
HQ: United Kingdom
Website
- Description: Provider of targeted small molecule therapeutics for cancer and autoimmune diseases, delivering drug candidates for licensing at pre-clinical or early clinical stages. Pipeline includes SDC-1801 and SDC-1802 (TYK2/JAK1 inhibitors) and SRA737 (clinical-stage, oral, selective Chk1 inhibitor).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Sareum company profile →
Anaveon
HQ: Switzerland
Website
- Description: Provider of IL-2-based immunotherapies developing selective IL-2 complexes that promote effector T cell functions as immune adjuvants for cancer, with candidates including ANV419, an IL-2 agonist that favors effector over regulatory T cells and shows clinical efficacy, and ANV600, a bispecific targeting IL-2 to tumor-specific cells, with Phase 1/2 planned for Q2/2024.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Anaveon company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Diatech Pharmacogenetics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Diatech Pharmacogenetics
2.2 - Growth funds investing in similar companies to Diatech Pharmacogenetics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Diatech Pharmacogenetics
4.2 - Public trading comparable groups for Diatech Pharmacogenetics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →